CHALLENGES & POTENTIALS OF PATIENT ENGAGEMENT
- Why diversity and inclusion in clinical trials are crucial?
- Understanding critical barriers to minority and underserved patient communities participation in clinical trials
- Equity and Inclusion of Rare Disease Patients – A Must on Many Levels
- What can the industry do to promote more diversity in the future?
- Latest guidelines that make healthcare more inclusive
Moderator:
Panelists:
- How knowledge can reduce the fear of Pharma and ultimately save lives.
- What do we really know about patient safety, both as an industry and an individual and what are the challenges we face?
- How can technology play a role in ensuring patient safety, compliance and pharmacovigilance?
- How we can leverage individual and collective data to ensure proper care and Quality of life while reducing damage, saving time and money.
- Patient engagement activities incorporating robust and meaningful patient engagement experiences to inform
regulatory work
Considerations in patient engagement
Resources to help engage with FDA
- Support different learning styles to ensure patients have equal access to education
- Patient centricity for better health outcomes
- How to determine cultural nuances and understandings to care
- The importance of data democratization
- Common challenges in clinical data review that hinders clinical trials
- Strategies in overcoming these challenges
- How to seamlessly integrate data from a variety of sources?
- How to improve safety review efficiencies and reduce the timeline to critical studies?
- Understanding complexities and addressing challenges faced by the industry in setting up end-to end supply chain for cell and gene therapies
- Best practices and lessons learned that guarantees effective manufacturing and delivery of CGTs to the patients who needs them the most
- Robust technologies and innovative platforms that connects therapies with patients both in clinical and commercial scale
This presentation will highlight how companies can advance health equity through people- and patient- centered frameworks. Learning objectives include:
- Specific domains of action for addressing health equity through people and patient engagement;
- Success measures of efforts to advance health equity;
- Different interpretations of decision making across stakeholders
- Value on patient outcomes and engagement (case studies)
- Introduce the working model of decision making.
- Putting the patient first achieves the best experience and outcome for that person and their family
- Improve communication from staff shift-changes in a hospital to getting the patient discharged faster
- Setting expectations soon
- Updating goals and outcomes; timely
- Recognising key areas to ensure patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development and evaluation.
- Patient’s input to improve quality, relevance, safety and efficacy of drug development
- Challenges and opportunities for patient-centric product design
- The role of respective stakeholders and the way they interact, from the early steps of drug development to access inreal life?
Moderator:
Panelists:
- Understanding the drivers for innovation in pharma
- Partnering with patients and placing patient well-being at the core of all initiatives
- Real-world data and patient-reported outcomes presents the power and the potential to redesign healthcare
- Innovative approaches for direct-to-patient assume significant importance for driving patient-centricity
- Technologies that enhance the patient-centricity in pharma
Moderator:
Panellist: